Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Trevi Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Trevi Therapeutics, Inc.

TRVI

Trevi Therapeutics, Inc.

About Trevi Therapeutics, Inc.

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release nalbuphine formulation targeting chronic cough associated with IPF, non-IPF ILD, and refractory chronic cough. Leveraging opioid receptor modulation, it aims to address unmet medical needs with potential advantages over existing therapies. The company focuses on clinical development, regulatory approval, and commercialization, competing with other innovative treatments in respiratory and dermatologic indications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Trevi Therapeutics, Inc.

1
1
Trevi Therapeutics, Inc. Trevi Therapeutics Reports $13.2 Million Net Loss in Q1 2026 Amid Increased R&D Expenses

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Trevi Therapeutics, Inc. Trevi Therapeutics Reports $42.8 Million Net Loss for 2025, Plans Phase 3 Trials

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Trevi Therapeutics, Inc. Trevi Therapeutics Reports Q3 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Trevi Therapeutics, Inc. Trevi Therapeutics Reports Q2 2025 Financial Results with Improved Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Trevi Therapeutics, Inc. Trevi Therapeutics Reports Q1 2025 Financial Results with $10.34 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Trevi Therapeutics, Inc. Trevi Therapeutics Reports $47.9 Million Net Loss for 2024, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Trevi Therapeutics, Inc. Trevi Therapeutics Reports Significant Financial Decline, Net Loss of $13.2M in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments